17 November 2021 Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP) signed a drug development agreement with Oxford StemTech, the custom cell reprogramming spec... Read more
22 September 2021 Oxford Cannabinoid Technologies' deal for exclusive access to Canopy Growth's cannabinoid library Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP) , is pleased to announce that on 21 September 2021 it signed an exclusive licensing agreemen... Read more
18 May 2021 Start-up focused on painkilling effects of cannabis to list in London Oxford Cannabinoid Technologies emerged from university research project into potential treatments. Oxford Cannabinoid Technologies, a biotech com... Read more
23 July 2020 OCT appoints new Chief Scientific Officer Oxford Cannabinoid Technologies ('OCT'), a UK-based biotechnology firm researching the potential of cannabinoids for treating a range of acute and chr... Read more
17 June 2020 OCT in OpenAccess Government, Part 5 - Treating Covid-19 In this final article of a series of five, Oxford Cannabinoid Technologies will discuss their expertise on the use of cannabinoids in medicine when it... Read more
19 April 2020 OCT researchers publish new study examining genes involved in treating neuropathic pain Oxford Cannabinoid Technologies ('OCT'), a UK-based biotechnology firm researching and developing the potential of drug compounds targeting the endoca... Read more
03 April 2020 OCT announces pre-clinical development of new cannabinoid compound 'OCT461201' to treat IBS Oxford Cannabinoid Technologies (�OCT�), a UK-based biotechnology firm researching the potential of cannabinoid-based medications for treating a range... Read more
30 March 2020 OCT in OpenAccess Government, Part 4 - Epilepsy In the fourth of a series of five articles, Oxford Cannabinoid Technologies discuss their expertise on cannabinoids in medicine. Following the previou... Read more
07 January 2020 OCT in OpenAccess Government, Part 3 - Psoriasis and Rheumatoid Arthritis Following the first two articles that discussed the treatment of cancer and pain, this third piece will focus on the use of cannabinoids to treat psor... Read more
11 October 2019 OCT in OpenAccess Government, Part 2 - Pain In the second of a series of five articles, Oxford Cannabinoid Technologies will discuss their expertise on the use of cannabinoids in medicine. Read more
22 August 2019 OCT in OpenAccess Government, Part 1 - Cancer In the first of a series of five articles, Oxford Cannabinoid Technologies will discuss their expertise on the medicinal use of cannabis derivatives Read more
09 August 2019 Evening Standard: the start-up hoping to unlock the secrets of medical cannabis Whilst the wonders of cannabis have been touted for conditions such as cancer and arthritis, relatively little is known about the green leaf and its s... Read more
03 April 2019 Bloomberg: OCT seeks big pharma funding Bloomberg�s Sam Unsted sat down with Neil Mahapatra to discuss OCT�s $50 million investment drive Read more
28 June 2018 Casa Verde Capital and Imperial Brands invest in OCT Oxford Cannabinoid Technologies ('OCT'), a biotechnology firm researching the potential of cannabinoid-based medications, announces today it has close... Read more
16 March 2017 Kingsley and Oxford University start £10m medical cannabis research project Oxford university is to launch a £10m research programme in medical marijuana with venture capital funding, in the hope of developing treatments for p... Read more
16 March 2017 Kingsley Capital Partners announces launch of Oxford Cannabinoid Technologies to unlock the potential of medicinal cannabis Kingsley Capital Partners ("Kingsley") today announces the launch of Oxford Cannabinoid Technologies ("OCT"), a UK biopharmaceutical business that wil... Read more